Together with national partners and as part of a European regulatory network, the MEB is continuously responsible for the assessment and monitoring of authorised products for the entire lifecycle.

Synergy is pursued within these national and EU relationships:

  •     between scientific and clinical, toxicological and pharmaceutical expertise
  •     in the distribution of tasks
  •     in creating greater efficiency and public confidence in the system.

The contribution to the team effort of creating the European marketing authorisation and pharmacovigilance system is a key strategic priority for the MEB. The MEB actively contributes on a European level through participation in a large number of platforms both within the European Medicines Agency (EMA) and beyond.